BioNTech to Open New Manufacturing Facility in Marburg to Expand Vaccine Production

Subheading: Expansion to Increase Production Capacity to 250 Million Doses

Paragraph 1:

German biotechnology company, BioNTech, is set to open a new manufacturing facility in Marburg, Germany. This move is part of the company's plan to increase its production capacity of the mRNA-based COVID-19 vaccine, BNT162b2, developed in collaboration with Pfizer.

Paragraph 2:

The Marburg facility will be the first to manufacture an mRNA-based vaccine approved for use against the coronavirus. mRNA vaccines are a new type of vaccine that utilizes genetic material to instruct cells to produce specific proteins, in this case, the spike protein of the SARS-CoV-2 virus.

Paragraph 3:

BioNTech aims to produce up to 250 million doses of BNT162b2 in the first half of 2021. The expansion of production capacity will increase the availability of vaccines, aiding in the global effort to combat the COVID-19 pandemic.